The role of biomarkers in the diagnosis, prognosis and management of MS
In this interactive discussion, Prof. Dr Eva Kubala Havrdová and Prof. Ludwig Kappos talk about the increasingly important role of biomarkers in the monitoring and management of MS, and how they would employ them in clinical practice.view bio and disclosures 1/2 Next Interview
The impact of MS on women of childbearing potential
In this interactive discussion, Prof. Eva Kubala Havrdová and Prof. Ludwig Kappos talk about the key considerations for women with MS who may want to have children, the impact of the disease and treatments, and how healthcare practitioners can best guide and support them along this journey.view bio and disclosures 2/2 Leave Feedback
Learning Objectives & Overview
With the availability of disease-modifying therapies in MS, achieving an early diagnosis and identifying optimal personalized treatment is essential to improving long term outcomes,1 and treatment goals have shifted from delaying disability to achieving ‘no evidence of disease activity’. While many measures involve clinical factors (relapses, gadolinium-enhancing lesions), biomarkers of disease activity could also be used to closely monitor disease progression and therapeutic efficacy.1 Also, as MS is most commonly diagnosed in young women, it is important that family planning and pregnancy are considered when starting any disease-modifying treatments.2,3
In these two videos, experts in the field of MS will discuss these key topics, their personal experiences, and how best to achieve optimal patient outcomes in real-world practice.
After watching this activity, participants should be better able to:
- Describe the importance of biomarkers in the diagnosis, prognosis and management of MS
- Understand how biomarkers may be used to optimize treatment decisions and improve patient outcomes
- Discuss key considerations for the management of MS in women of childbearing potential
Faculty & Disclosures
Prof. Dr Eva Kubala Havrdová
General University Hospital, Charles University, Prague, Czech Republic
Advisory Boards: Actelion, Biogen, Celgene, Genzyme, Novartis
Consultancy: Actelion, Biogen, Celgene, Genzyme, Merck Serono, Novartis
Travel or speaker honoraria: Actelion, Biogen, Celgene, Genzyme, Merck Serono, Novartis, Roche
Prof. Ludwig Kappos
University Hospital and University of Basel, Basel, Switzerland
Steering Committee, Advisory Board, Consultancy and/or support for educational activities: Allergan, Almirall, Baxalta, Bayer Healthcare, Biogen, Celgene/Receptos, CSL-Behring, Desitin, Excemed, Eisai, Genzyme, Japan Tobacco, Merck, Minoryx, Novartis, Pfizer, F. Hoffmann–La Roche Ltd, Roche, Sanofi Aventis, Santhera, Teva
- Smith AL, Cohen, JA, Hua, LH. Therapeutic Targets for Multiple Sclerosis: Current Treatment Goals and Future Directions. Neurotherapeutics. 2017; 14: 952–960.
- Dobson R, Dassan P, Roberts M, et al. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract Neurol. 2019;19:106–114.
- Krysko KM, Bove R, Dobson R, et al. Treatment of women with multiple sclerosis planning pregnancy. Curr Treat options Neurol. 2021;23:11.